Head-to-head · WeighScore
Evernow vs FlyteHealth
The verdict
Evernow takes it — 58.8/100 to 58.6/100, but only just.
Evernow grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Evernow is a women's-focused, menopause-centered telehealth platform that prescribes branded GLP-1 weight loss medications including Ozempic, Wegovy, Zepbound, and Mounjaro via US-licensed clinicians. FlyteHealth is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Evernow | FlyteHealth |
|---|---|---|
| WeighScore | 58.8/100 | 58.6/100 |
| Grade | C | C |
| Scorecard rank | #357 | #364 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #357 · C
Strengths
- Prescribes FDA-approved branded GLP-1s, not compounded
- Accepts insurance for video visits (BCBS, Anthem, UnitedHealthcare, Aetna)
- Integrates GLP-1 weight loss with menopause and HRT care
- Flexible one-time visit or low-cost membership models
Where it loses points
- Weight loss is one vertical alongside menopause and HRT care
- GLP-1 medication cost depends on insurance and is not posted
- State availability not specified on the site
Graded #364 · C
Strengths
- Care led by board-certified obesity-medicine physicians
- Multidisciplinary team with NPs, dietitians, and care coordinators
- Published outcomes of about 13 to 16 percent weight loss over 12 months
- High GLP-1 medication adherence (around 86 percent in reported data)
- Comprehensive cardiometabolic care beyond GLP-1 alone
Where it loses points
- Distributed primarily via employers, payers, and health plans, not direct cash-pay
- Access is largely gated behind employer or plan sponsorship
- GLP-1 is prescribed only when appropriate, not guaranteed
- Self-pay pricing is not publicly listed (contact required)
- Less suited to consumers wanting fast direct-to-door GLP-1
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.